Caxton Associates LP Veracyte, Inc. Transaction History

Caxton Associates LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$15.45 - $29.52 $159,104 - $303,996	-10,298 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$21.94 - $42.51 $225,938 - $437,767	10,298 New	10,298 $284,000
Q3 2019 Nov 14, 2019	SELL	$23.87 - $30.93 $403,952 - $523,428	-16,923 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$22.1 - $28.56 $99,648 - $128,777	-4,509 Reduced 21.04%	16,923 $482,000
Q1 2019 May 15, 2019	BUY	$12.0 - $25.76 $257,184 - $552,088	21,432 New	21,432 $536,000

254

82.1M

42.3K

18.2K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.42B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.